Skip to main content

Advertisement

Log in

Sustained release varnish containing chlorhexidine for prevention of Streptococcus mutans biofilm formation on voice prosthesis surface: an in vitro study

  • Original Article
  • Published:
International Microbiology Aims and scope Submit manuscript

Abstract

Objectives

In this study, we aimed to develop a novel, sustained release varnish (SRV) for voice prostheses (VP) releasing chlorhexidine (CHX), for the prevention of biofilm formation caused by the common oral bacteria Streptococcus mutans on VP surfaces.

Methods

This study was performed in an in vitro model as a step towards future in vivo trials. VPs were coated with a SRV containing CHX (SRV-CHX) or SRV alone (placebo-SRV) that were daily exposed to S. mutans. The polymeric materials of SRV were composed of ethylcellulose and PEG-400. Biofilm formation was assessed by DNA quantification (qPCR), crystal violet staining, confocal laser scanning microscopy (CLSM), scanning electron microscopy (SEM), and kinetics experiments.

Results

The amount of DNA in the biofilms formed by S. mutans on VP surfaces coated once with SRV-CHX (1.024 ± 0.218 ng DNA/piece) was 58.5 ± 8.8% lower than that of placebo-SRV-coated VPs (2.465 ± 0.198 ng DNA/piece) after a 48-h exposure to S. mutans (p = 0.038). Reduced biofilm mass on SRV-CHX-coated VPs was visually confirmed by CLSM and SEM. CV staining of SRV-CHX single-coated VPs that have been exposed to S. mutans nine times showed a 98.1 ± 0.2% reduction in biofilm mass compared to placebo-SRV-coated VPs (p = 0.003). Kinetic experiments revealed that SRV-CHX triple-coated VPs could delay bacterial growth for 23 days.

Conclusions

Coating VPs with SRV-CHX has an inhibitory effect on biofilm formation and prevents bacterial growth in their vicinities. This study is a proof-of-principle that paves the way for developing new clinical means for reducing both VPs’ bacterial biofilm formation and device failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.

References

Download references

Acknowledgements

The authors thank Dr. Mark Tarshish and Dr. Vitaly Gutkin (Hebrew University, Jerusalem, Israel) for the assistance with the CLSM and SEM, respectively. Menachem Gross, Fadi Ashqar, and Ronit Vogt Sionov have equal contribution to this study.

Funding

This study was supported by a grant from the Israeli Cancer Association (Ref Number—20180025).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: Menachem Gross, Michael Friedman, Doron Steinberg.

Data curation: Menachem Gross, Ron Eliashar, Ronit Vogt Sionov, Mark Feldman.

Formal analysis: Fadi Ashqar, Batya Zaks, Ronit Vogt Sionov, Mark Feldman.

Funding acquisition: Menachem Gross, Doron Steinberg.

Investigation: Menachem Gross, Fadi Ashqar, Ron Eliashar, Batya Zaks, Ronit Vogt Sionov, Mark Feldman, Doron Steinberg.

Methodology: Menachem Gross, Batya Zaks, Ronit Vogt Sionov, Mark Feldman Irith Gati, Doron Steinberg.

Project administration: Ron Eliashar, Doron Steinberg, Menachem Gross.

Resources: Michael Friedman, Doron Steinberg, Menachem Gross.

Software: Danielle Duanis-Assaf, Ronit Vogt Sionov.

Supervision: Michael Friedman, Doron Steinberg, Menachem Gross.

Validation: Danielle Duanis-Assaf, Ronit Vogt Sionov, Mark Feldman, Doron Steinberg.

Visualization: Mark Feldman, Danielle Duanis-Assaf, Ronit Vogt Sionov.

Writing—original draft: Menachem Gross.

Writing—review and editing: Menachem Gross, Doron Steinberg, Ronit Vogt Sionov.

Corresponding author

Correspondence to Menachem Gross.

Ethics declarations

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Highlights:

1. Speech rehabilitation with voice prosthesis is the treatment of choice in patients following total laryngectomy.

2. Biofilm development on voice prosthesis limits the lifetime of the product resulting in early replacement of the prosthesis.

3. Chlorhexidine has antiseptic and antifungal properties that prevent biofilm formation.

4. Sustained release varnish is a method for local slow release of an agent from a coated prosthesis or device, thereby prolonging the duration of the drug at the target site.

5. Utilization of sustained release varnish of chlorhexidine can prolong the lifetime of the VP via a delay of biofilm formation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gross, M., Ashqar, F., Sionov, R.V. et al. Sustained release varnish containing chlorhexidine for prevention of Streptococcus mutans biofilm formation on voice prosthesis surface: an in vitro study. Int Microbiol 25, 177–187 (2022). https://doi.org/10.1007/s10123-021-00205-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10123-021-00205-w

Keywords

Navigation